<div id="readability-page-1"><p>Norges Bank bought a new stake in  Doximity, Inc. (NASDAQ:DOCS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 101,155 shares of the company's stock, valued at approximately $6,205,000. Norges Bank owned 0.05% of Doximity at the end of the most recent reporting period.</p><ul><li>Market Shift: These 3 Stocks Are Winning While Big Tech Lags</li></ul><p>Several other hedge funds have also recently added to or reduced their stakes in DOCS. Hantz Financial Services Inc. grew its stake in shares of  Doximity by 148.9% in the second quarter. Hantz Financial Services Inc. now owns 453 shares of the company's stock worth $28,000 after purchasing an additional 271 shares in the last quarter.  National Bank of Canada FI acquired a new stake in  Doximity in the first quarter worth about $33,000.  Brooklyn Investment Group lifted its holdings in  Doximity by 70.7% in the first quarter. Brooklyn Investment Group now owns 746 shares of the company's stock worth $43,000 after purchasing an additional 309 shares during the period.  Smartleaf Asset Management LLC grew its position in  Doximity by 176.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 781 shares of the company's stock valued at $46,000 after buying an additional 498 shares in the last quarter.  Finally, Cullen Frost Bankers Inc. increased its stake in  Doximity by 29.7% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,427 shares of the company's stock valued at $88,000 after buying an additional 327 shares during the period. Institutional investors own  87.19% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In other Doximity news, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $66.44, for a total transaction of $132,880.00. Following the sale, the director owned 19,839 shares in the company, valued at approximately $1,318,103.16. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy S. Cabral sold 20,000 shares of the company's stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $75.00, for a total transaction of $1,500,000.00. Following the sale, the director directly owned 3,221 shares of the company's stock, valued at $241,575. This represents a 86.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 32,000 shares of company stock valued at $2,339,580. 31.30% of the stock is owned by corporate insiders. </p><h2>Doximity Stock Performance</h2><ul><li>Doximity is the Facebook and LinkedIn of the Medical Community</li></ul><p>NASDAQ DOCS opened at $45.17 on Wednesday. Doximity, Inc. has a 1 year low of $44.98 and a 1 year high of $85.21. The business's fifty day moving average is $59.65 and its two-hundred day moving average is $61.64. The stock has a market capitalization of $8.50 billion, a P/E ratio of 45.17, a P/E/G ratio of 4.10 and a beta of 1.38. </p><p>Doximity (NASDAQ:DOCS - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.07. Doximity had a return on equity of 21.75% and a net margin of 36.60%.The firm's revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 EPS.  On average, research analysts forecast that  Doximity, Inc. will post 0.99 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><ul><li>Doximity is an Overlooked Medical Ecosystem AI Play </li></ul><p>A number of analysts have recently weighed in on the stock. Evercore ISI reduced their price target on shares of Doximity from $81.00 to $70.00 and set an &#34;outperform&#34; rating for the company in a research note on Friday, November 7th. Canaccord Genuity Group cut their target price on Doximity from $67.00 to $58.00 and set a &#34;hold&#34; rating for the company in a research report on Monday, November 10th. KeyCorp increased their price target on Doximity from $75.00 to $80.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 8th. Robert W. Baird boosted their price objective on Doximity from $75.00 to $80.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, September 11th. Finally, BMO Capital Markets initiated coverage on Doximity in a report on Thursday, November 13th. They issued a &#34;market perform&#34; rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued  a Buy rating, eight have given a Hold rating and two have assigned  a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $67.95.</p><p><b>Get Our Latest Stock Report on DOCS</b></p><h2>About Doximity</h2> (Free Report)<p>Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Doximity</li><li>Pros And Cons Of Monthly Dividend Stocks</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>How to Capture the Benefits of Dividend Increases</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>What is Insider Trading? What You Can Learn from Insider Trading</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9DUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9DUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Doximity Right Now?</h2><p>Before you consider Doximity, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.</p><p>While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DOCS

<p>Norges Bank acquired a new stake in Doximity, Inc. during Q2, purchasing 101,155 shares valued at approximately $6.21 million. This represents 0.05% ownership of Doximity. Several other hedge funds also adjusted their positions in the company. Doximity's stock performance and insider trading activities were highlighted, along with recent analyst ratings and price target adjustments.</p>

Norges Bank Invests $6.21 Million in Doximity, Inc. $DOCS